Arterys Cardio AI

by Tempus AI, Inc.

🟡Acquired / Merged

Cloud-based cardiac MRI analysis software that used machine learning to assist clinicians with image segmentation, ventricular measurements, and cardiac function assessment. Tempus acquired Arterys in 2022.

HealthcareFounded by Fabien Beckers, John Axerio-Cilies, and Albert HsiaoVisit website →
🔍 Last checked: 8/29/2026 · Confidence: 98%

Acquisition Details

Tempus announced its acquisition of Arterys in October 2022. Arterys technology was subsequently incorporated into Tempus's medical-imaging portfolio, while the former Arterys homepage now redirects to Tempus.

🩺 Health Signals

3d ago
HTTP Status
429
Response
SSL
Confidence
98%
Domain expires
Last content change
Last tweet
API status

📅 Timeline

2017-01-05

Cardio AI receives FDA clearance

Arterys announced FDA 510(k) clearance for its cloud-based Cardio AI application, which applied deep learning to cardiac MRI image analysis.

2017-11-02

Series B funding announced

Arterys announced a $30 million Series B financing round led by Temasek, with participation from investors including GE Ventures and Fosun.

2020-05-05

Series C funding announced

Arterys announced a $28 million Series C round led by Benslie Investment Group and Temasek, intended to expand its medical-imaging AI platform.

2022-10-04

Tempus acquires Arterys

Tempus announced that it had acquired Arterys to add cloud-based medical-imaging AI capabilities to its precision-medicine platform.

🔄 Alternatives to Arterys Cardio AI

🪦 Other dead Healthcare tools

Frequently Asked Questions

What is Arterys Cardio AI?

Arterys Cardio AI is cloud-based medical-imaging software designed to assist clinicians in analyzing cardiac MRI studies, including segmentation and measurements of ventricular structure and function.

Is Arterys Cardio AI still available?

Arterys was acquired by Tempus in October 2022. Its capabilities are now associated with Tempus's medical-imaging portfolio, so availability and branding should be confirmed directly with Tempus.

Who acquired Arterys Cardio AI?

Tempus acquired Arterys in October 2022. Tempus develops precision-medicine and clinical-data products, including AI-supported medical imaging.

Did Arterys Cardio AI receive FDA clearance?

Yes. Arterys announced FDA 510(k) clearance for its Cardio AI cloud application in January 2017. Clearance applies to the specified intended use and does not mean the software replaces clinical judgment.

What are alternatives to Arterys Cardio AI?

The provided catalogue contains no close cardiac-imaging clinical competitors. Broader AI and machine-learning alternatives include Akkio, Obviously AI, and Hugging Face, though these are not substitutes for regulated cardiac MRI software.